VKTX | Ticker Profile - Titan Protect

VKTX

Viking Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$28.45

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.97

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-70.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$97.50

+243% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 18 analysts covering this stock

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

https://www.vikingtherapeutics.com

Country: United States Employees: 59 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.028

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0044

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.391

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-29.1%

Historical annualised return based on price data

Max Drawdown

-74.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

173

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.71

Less volatile than the market — more defensive

52W High

$43.15

34% below the year high

52W Low

$22.96

24% above the year low

Avg Volume

2,295,365

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

20.3%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.15

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

5.72

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.67

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-177,354,752

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-472,335,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$125.00

Target Median

$97.50

Target Low

$34.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go